Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719858 | 0.94 | CACNA2D1 (0.37) | KCNH2CACNA2D1CRHR1TLR8DRD2 | |
| SCHEMBL4724189 | 0.88 | ELANE (0.35) | CACNA2D1CRHR1TLR8 | |
| SCHEMBL4724625 | 0.87 | TLR8 (0.43) | KCNH2CACNA2D1TLR8TLR7 | |
| SCHEMBL4721803 | 0.81 | ELANE (0.42) | CACNA2D1TLR8 | |
| SCHEMBL4724624 | 0.80 | APP (0.41) | TLR8TLR7 | |
| SCHEMBL4720683 | 0.77 | TLR8 (0.43) | TLR8TLR7CYP2D6 | |
| SCHEMBL4724840 | 0.76 | TLR8 (0.39) | TLR8 | |
| SCHEMBL4723728 | 0.76 | NCF1 (0.44) | TLR8CYP2D6 | |
| SCHEMBL4722779 | 0.75 | TLR8 (0.55) | TLR8TLR7 | |
| SCHEMBL9637930 | 0.71 | ALDH1A1 (0.41) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | KCNH2 402/4885CACNA2D1 2309/4885CRHR1 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.